Funding for this research was provided by:
Volition Diagnostics UK Ltd
Fred and Vola Palmer Chair in Comparative Oncology
Received: 8 March 2021
Accepted: 10 June 2021
First Online: 29 June 2021
: All animal studies were approved by the Texas A&M University Animal Care and Use Committee (AUP #2017 − 0350). Client-owned animals were evaluated with the informed consent of the owner (AUP #2019 − 0211). 4)All methods were carried out in accordance with relevant guidelines and regulations.No humans were involved in this study.No agents were administered to dogs in any way during this study.
: Not applicable.
: JT, TK, MB and TB are employees of Volition Diagnostics UK Ltd & Volition America, which have patents covering Nu.Q technology and are developers of Nu.QTM assays. Volition Veterinary is a joint venture between Belgian Volition and Texas A&M University. HWR is a paid consultant of Volition Veterinary. TM and JJ have no conflicts of interest to declare. Additional salary support for TM was provided by the Fred and Vola Palmer Chair in Comparative Oncology held by HWR. The Palmers did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support for the authors’ salaries (T.M.). This does not alter our adherence to BMC policies on sharing data and materials.